Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating CC-97540 in relapsing and progressive forms of multiple sclerosis and refractory myasthenia gravis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Myasthenia Gravis

Drugs mentioned

• CC-97540

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Multiple Sclerosis, Myasthenia Gravis | Phase 1 | Status: RECRUITING